S
Surya Pharmaceutical Ltd
SURYAPHARM
Surya Pharmaceutical Ltd
Healthcare Pharmaceuticals & Biotechnology
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Surya Pharmaceutical Ltd insights
29 extracted metrics + investor summaries across FY06–FY13.
Tapetide Score
Data-driven rating, 0–100. How it works →
Technical Indicators
Key Insights
Weaknesses
5- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -34.2% over past five years.
- Company has a low return on equity of -51.2% over last 3 years.
- Company has high debtors of 1,363 days.
- Working capital days have increased from 2,034 days to 5,556 days
Growth Rate
Revenue Growth
-178.00% →
Net Income Growth
126.00% →
Cash Flow Change
-
ROE
-294.00% ↘
ROCE
-
EBITDA Margin (Avg.)
-
Quarterly Results
| Mar 2013 | Jun 2013 | Sep 2013 | Dec 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Dec 2014 | |
|---|---|---|---|---|---|---|---|---|
| Sales | -15 | 6 | 5 | 1 | 2 | 0 | 0 | 0 |
| Expenses | 110 | 9 | 8 | 618 | 13 | 2 | 2 | 1 |
| Operating Profit | -125 | -3 | -3 | -617 | -11 | -1 | -1 | -1 |
| OPM % | — | -54% | -69% | -102843% | -492% | -251% | -293% | — |
| Other Income | -18 | 0 | 0 | -219 | 0 | 0 | 0 | 0 |
| Interest | 38 | 62 | 69 | 16 | 108 | 0 | 0 | 0 |
| Depreciation | 34 | 16 | 16 | 16 | 16 | 16 | 16 | 16 |
| PBT | -215 | -81 | -88 | -868 | -134 | -17 | -17 | -17 |
| Tax % | 0% | 0% | 0% | 0% | -331% | 0% | 0% | 0% |
| Net Profit | -215 | -81 | -88 | -868 | 310 | -17 | -17 | -17 |
| EPS in Rs | -10.6 | -3.97 | -4.35 | -42.8 | 15.28 | -0.83 | -0.84 | -0.85 |
Profit & Loss
| Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 239 | 283 | 486 | 723 | 1,134 | 1,600 | 1,623 | 60 | 3 |
| Expenses | 192 | 231 | 400 | 602 | 973 | 1,337 | 1,765 | 214 | 18 |
| Operating Profit | 47 | 52 | 86 | 120 | 161 | 263 | -142 | -154 | -14 |
| OPM % | 20% | 18% | 18% | 17% | 14% | 16% | -9% | -255% | -476% |
| Other Income | 0 | 3 | 5 | 1 | 13 | 3 | -38 | -35 | 0 |
| Interest | 14 | 16 | 26 | 41 | 62 | 108 | 179 | 207 | 108 |
| Depreciation | 6 | 8 | 9 | 16 | 21 | 27 | 35 | 62 | 63 |
| PBT | 27 | 30 | 56 | 64 | 90 | 132 | -393 | -459 | -185 |
| Tax % | 21% | 22% | 26% | 12% | 16% | 24% | -31% | -34% | — |
| Net Profit | 21 | 24 | 42 | 56 | 76 | 100 | -273 | -302 | 259 |
| EPS in Rs | — | 16.37 | 28.83 | 38.8 | 52.57 | 5.2 | -13.47 | -14.89 | 12.76 |
| Div. Payout % | 0% | 0% | 3% | 3% | 3% | 3% | 0% | 0% | — |
Balance Sheet
| Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 11 | 14 | 14 | 14 | 14 | 19 | 20 | 20 |
| Reserves | 80 | 124 | 164 | 216 | 289 | 501 | 227 | -75 |
| Borrowings | 148 | 196 | 318 | 501 | 708 | 1,441 | 1,754 | 2,009 |
| Other Liabilities | 54 | 60 | 124 | 218 | 375 | 205 | 126 | 63 |
| Total Liabilities | 293 | 394 | 621 | 949 | 1,386 | 2,166 | 2,128 | 2,017 |
| Fixed Assets | 62 | 81 | 162 | 213 | 229 | 404 | 728 | 671 |
| CWIP | 31 | 61 | 30 | 88 | 199 | 232 | 7 | 8 |
| Investments | 0 | 0 | 0 | 0 | 6 | 26 | 34 | 16 |
| Other Assets | 200 | 251 | 429 | 648 | 953 | 1,504 | 1,358 | 1,323 |
| Total Assets | 293 | 394 | 621 | 949 | 1,386 | 2,166 | 2,128 | 2,017 |
Cash Flow
| Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | |
|---|---|---|---|---|---|---|---|---|
| Operating | 24 | -5 | 68 | -8 | 165 | 69 | 386 | 166 |
| Investing | -48 | -56 | -54 | -121 | -144 | -245 | -150 | -8 |
| Financing | 61 | 25 | 13 | 103 | -11 | 174 | -241 | -160 |
| Net Cash Flow | 38 | -36 | 26 | -25 | 10 | -2 | -6 | -3 |
| Free Cash Flow | -24 | -62 | 9 | -133 | 18 | -165 | 262 | 157 |
| CFO/OP | 58 | 0 | 85 | 6 | 108 | 32 | -356 | -201 |
Ratios
| Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 77 | 95 | 62 | 69 | 49 | 66 | 53 | 1,363 |
| Inventory Days | 172 | 235 | 238 | 247 | 271 | 309 | 179 | 1,254 |
| Days Payable | 63 | 63 | 88 | 117 | 108 | 20 | 10 | 56 |
| Cash Conversion Cycle | 185 | 266 | 212 | 199 | 212 | 355 | 222 | 2,561 |
| Working Capital Days | 171 | 251 | 213 | 220 | 184 | 308 | 238 | 5,556 |
| ROCE % | — | 16% | 20% | 18% | 17% | 16% | -11% | -12% |
Documents
Frequently Asked Questions about Surya Pharmaceutical Ltd
What does Surya Pharmaceutical Ltd do?
Surya Pharmaceuticals Ltd. ventures as a pharmaceutical company. The businesses include Contract Manufacturing, Custom Synthesis, FTE Research, and the manufacture and marketing of pharmaceuticals products and services to clients worldwide. Surya Pharmaceuticals' wide range of product portfolio i...
Where is Surya Pharmaceutical Ltd (SURYAPHARM) listed?
Surya Pharmaceutical Ltd is listed on the Indian stock exchanges. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Surya Pharmaceutical Ltd belong to?
Surya Pharmaceutical Ltd operates in the Healthcare sector within the Pharmaceuticals & Biotechnology industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
How can I research Surya Pharmaceutical Ltd on Tapetide?
On Tapetide, you can view Surya Pharmaceutical Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.
Company Information
Surya Pharmaceuticals Ltd. ventures as a pharmaceutical company. The businesses include Contract Manufacturing, Custom Synthesis, FTE Research, and the manufacture and marketing of pharmaceuticals products and services to clients worldwide. Surya Pharmaceuticals' wide range of product portfolio includes Active Pharmaceutical Ingredients (APIs), Fine Intermediates, Finished Drug Formulations (FDFs), Phyto Pharmaceuticals and CRAMS.
Website suryapharma.com
Face Value ₹ 1